Login to Your Account

U.K.'s early access scheme working but challenges remain

By Nuala Moran
Staff Writer

Monday, May 9, 2016

LONDON – Two years after it was instituted, the U.K.'s Early Access to Medicines Scheme (EAMS) has succeeded in getting drugs to patients in advance of a formal marketing approval, but the aim that therapies arrive a year beforehand has not been met, and the fact the scheme is not funded makes it hard for small biotechs to participate.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription